Some great quotes in that article. This sector will be short heaven until all these companies either readjust to valuations for reasonable price increases. Concordia won't have that opportunity, it's too overextended.
"Drugmakers in recent years have repeatedly boosted prices for many drugs at rates well above the broader rate of inflation, and have introduced new drugs at prices
...more